all report title image
  • Published On : Nov 2022
  • Code : CMI1035
  • Industry : Medical Devices
  • Pages : 175
  • Formats :

Auto-injector is a medical device which is used for injecting oneself with a single, preloaded dose of a drug. It is consists of a spring-loaded syringe which gets activated when the device is pushed firmly against the body. Auto-injector devices are useful for the rapid administration of a particular drugs and antidotes. An auto-injector has a drug cartridge with an embedded needle for subcutaneous or intramuscular injection, which is usually painless. Then, drugs are slowly delivered by the auto-injector across a large area in the muscle, which increases the drug absorption and the drug effects. Epinephrine auto-injector is a type of auto-injector widely used for people at risk of anaphylaxis. They can also be used by those who have not been medically trained. Auto-injectors are often used in the military to protect personnel from chemical warfare agents.

The global auto-injectors market is estimated to be valued at US$ 4,497.7 million in 2022 and is expected to exhibit a CAGR of 18.0% during the forecast period (2022-2030).

Figure 1. Global Auto-injectors Market Share (%), by Product Type, 2022

Auto-injectors  | Coherent Market Insights

Global Auto-injectors Market - Driver

Increasing inorganic strategies such as agreement is expected to boost the growth of global auto-injectors market. For instance, in May 2022, Stevanato Group, a manufacturer and distributor of drug containment, announced that they had signed an agreement with Owen Mumford Ltd., a manufacturer of medical device, for its Aidaptus auto-injector. This agreement will bring value to customers, matching world-class device expertise with premium manufacturing capabilities. Aidaptus auto-injector is a two-step, single use auto-injector with a versatile design that accommodates both 1 mL and 2.25 mL prefilled glass syringes in the same base device.

Figure 2. Global Auto-injectors Market Value (US$ Million), by Region, 2022

Auto-injectors  | Coherent Market Insights

Global Auto-injectors Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global auto-injectors market due to the increasing development of vaccines and treatment against COVID-19. For instance, in May 2022, the European Medicine Agency (EMA) approved Vaxzevria in the European Union (EU) as a third dose booster in adults. Thus, the increasing approvals of vaccines will demand the injectable drug delivery devices like needles and syringes.

CMI table icon

Auto-injectors Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 4,497.7 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 18.0% 2030 Value Projection: US$ 16,953.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Prefilled Auto-injectors, Fillable Auto-injectors
  • By Disease Indication: Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Others (Diabetes, Psoriasis, etc.)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Becton, Dickinson and Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Xeris Biopharma Holdings Inc., BlackHagen Design, GSK plc., Genentech, Inc., AstraZeneca, Owen Mumford Ltd., Stevanato Group, Jabil Inc., Pfizer, Inc., Mylan N.V., Novartis AG, Bayer AG, Janssen Pharmaceuticals, Inc., Antares Pharma, Eli Lilly and Company, Amgen Inc., Rafa Laboratories Ltd., Halozyme, Inc., Biogen, and Teva Pharmaceutical Industries Ltd.

Growth Drivers:
  • Adoption of inorganic strategies such as product launch and agreement by key market players
Restraints & Challenges:
  • Increasing number of product recalls by regulatory authorities such as U.S. Food and Drug Administration

Global Auto-injectors Market: Key Developments

Adoption of inorganic growth strategies such as product launch is expected to drive the global auto-injectors market. For instance, in May 2022, Jabil Inc., a medical device company, announced that they had launched the Qfinity auto-injector. It is a self-administered, reusable, and modular solution for subcutaneous (SC) drug that is delivered at a lower cost.

Global Auto-injectors Market: Restraint

Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration. For instance, in September 2021, a trulicity auto-injector, which is manufactured by Eli Lilly & Company, a pharmaceutical company, was recalled by the U.S. Food and Drug Administration due to labelling error. The auto-injector device was labeled as 0.75 mg/0.5 mL as it was actually contained 1.5 mg/0.5 mL of product. The recall affects 119,539 boxes of Trulicity 0.75 mg/0.5 mL single-dose pens, four pens per box (NDC 0002-1433-80), from lot D396436C.

Global Auto-injectors Market - Key Players

Major players operating in the global auto-injectors market include Becton, Dickinson and Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Xeris Biopharma Holdings Inc., BlackHagen Design, GSK plc., Genentech, Inc., AstraZeneca, Owen Mumford Ltd., Stevanato Group, Jabil Inc., Pfizer, Inc., Mylan N.V., Novartis AG, Bayer AG, Janssen Pharmaceuticals, Inc., Antares Pharma, Eli Lilly and Company, Amgen Inc., Rafa Laboratories Ltd., Halozyme, Inc., Biogen, and Teva Pharmaceutical Industries Ltd.

Auto- injector is a medical device which can deliver dose of medications. Auto injectors are easy to use and self-administration by patients is possible. Auto-injectors are disposable and there is a tremendous growth in the development of reusable auto-injectors with multiple dosing. Auto-injectors come under injectable drug delivery which is considered as the most effective route of administration for the effective delivery of drugs to the targeted site, which enhances the patient’s compliance to the drug. The Injectable delivery enhances the rapid absorption of drug from various sites such as subcutaneous, intravenous, and intramuscular. The injectable delivery increases the bioavailability of the drug at the systemic circulation, which offers availability of drug at intended site of action. Epinephrine auto-injector is a type of auto-injector widely used for people at risk of anaphylaxis. Auto-injectors enclose prefilled syringes or cartridges which are driven by a spring system. Auto-injectors are often used in the military to protect personnel from chemical warfare agents.

Market Dynamics

Adoption of inorganic growth strategies such as product launch by key market players is expected to drive the global auto-injectors market over the forecast period. For instance, in April 2020, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, announced that they had launched auto-injector for AJOVY, which is indicated for the preventive treatment of migraine in adults. This new auto-injector has several features such as easy handling including a button-free, push-down mechanism, audible cues that signal progress of administration, and a window that displays when the dose has been delivered.

Key features of the study:

  • This report provides an in-depth analysis of the global auto-injectors market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global auto-injectors market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Becton, Dickinson and Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Xeris Biopharma Holdings Inc., BlackHagen Design, GSK plc., Genentech, Inc., AstraZeneca, Owen Mumford Ltd., Stevanato Group, Jabil Inc., Pfizer, Inc., Mylan N.V., Novartis AG, Bayer AG, Janssen Pharmaceuticals, Inc., Antares Pharma, Eli Lilly and Company, Amgen Inc., Rafa Laboratories Ltd., Halozyme, Inc., Biogen, and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global auto-injectors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global auto-injectors market

Detailed Segmentation:

  • Global Auto-injectors Market, By Product Type:
    • Prefilled Auto-injectors
    • Fillable Auto-injectors
  • Global Auto-injectors Market, By Disease Indication:
    • Anaphylaxis
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Others (Diabetes, Psoriasis, etc.)
  • Global Auto-injectors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Auto-injectors Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Becton, Dickinson and Company*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Xeris Biopharma Holdings Inc.
    • BlackHagen Design
    • GSK plc.
    • Genentech, Inc.
    • AstraZeneca
    • Owen Mumford Ltd.
    • Stevanato Group
    • Jabil Inc.
    • Pfizer, Inc.
    • Mylan N.V.
    • Novartis AG
    • Bayer AG
    • Janssen Pharmaceuticals, Inc.
    • Antares Pharma
    • Eli Lilly and Company
    • Amgen, Inc.
    • Rafa Laboratories Ltd.
    • Halozyme, Inc.
    • Biogen
    • Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global auto-injectors market size is estimated to be valued at US$ 4,497.7 million in 2022 and is expected to exhibit a CAGR of 18.0% between 2022 and 2030.
Adoption of inorganic strategies such as product launch and agreement by key market players are expected to drive the market
Prefilled auto-injectors are the leading product type segment in the market
The key factors hampering growth of the market is increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration.
Major players operating in the market include Becton, Dickinson and Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Xeris Biopharma Holdings Inc., BlackHagen Design, GSK plc., Genentech, Inc., AstraZeneca, Owen Mumford Ltd., Stevanato Group, Jabil Inc., Pfizer, Inc., Mylan N.V., Novartis AG, Bayer AG, Janssen Pharmaceuticals, Inc., Antares Pharma, Eli Lilly and Company, Amgen Inc., Rafa Laboratories Ltd., Halozyme, Inc., Biogen, and Teva Pharmaceutical Industries Ltd.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo